Siemens Healthineers: A Recovering Stock That Still Needs Diagnostics to Deliver
Published on 07/29/2026 at 17:21 | Redaktion boerse-global.de
The shares of Siemens Healthineers have been on a tear this week, climbing 3.87 percent to €37.27 on Wednesday alone and notching an eight-day gain of just over 8 percent. The bounce has lifted the stock roughly 13 percent off its 52-week low of €32.84, a level it touched during a punishing spring sell-off. Yet for all the recent momentum, the question hanging over the equity is whether this rally can survive the next earnings report — or whether it will fizzle before the numbers land.
The backdrop to the recovery is a stock that remains deeply scarred. Even after the latest run, Siemens Healthineers trades about 25 percent below its 52-week high of €49.86 and has lost 17 percent since the start of the year. The damage was inflicted in May, when management slashed its full-year guidance. The culprit was a double blow: structural upheaval in China’s diagnostics market and rising inflation expectations that have pushed up costs for memory chips, raw materials and logistics.
The diagnostics division — the same unit that prompted the profit warning — is the key variable. In the second fiscal quarter, comparable revenue in the segment shrank 6.5 percent, almost entirely because of the deteriorating Chinese environment. The rest of the group held up better, with overall comparable growth of 3.1 percent, driven by imaging and precision therapy. But the diagnostics drag has been severe enough to force management to lower its adjusted earnings-per-share forecast to a range of €2.20 to €2.30, down from a previous ceiling of €2.40.
The upcoming third-quarter results, expected in the coming days though not yet officially dated, will be the first real test of whether that revised target is achievable. If the numbers show signs that the Chinese diagnostics business is stabilizing, the rally could gain legs. If the weakness persists or deepens, the stock could quickly slide back toward its recent lows.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
There are reasons for cautious optimism. Technically, the shares have decisively cleared their 50-day moving average of €34.75, now trading about 7 percent above it — a sign that short-term momentum has shifted. The relative strength index sits at 68.8, approaching the threshold that typically signals overbought conditions, but the move has been orderly rather than parabolic.
Fundamentally, the problems at diagnostics appear contained to that one segment. The core imaging and precision therapy businesses continue to perform, and the company has already begun preparations to potentially spin off or divest the diagnostics unit, though no formal timeline has been set. CFO Jochen Schmitz has flagged additional cost headwinds in the mid-to-high double-digit millions for the second half, driven by the same input-cost pressures that triggered the guidance cut. Whether those pressures are easing will be a critical data point in the Q3 release.
Meanwhile, the stock still has ground to cover before it can claim a genuine trend reversal. The 200-day moving average sits at €39.58, roughly 6 percent above the current price. Until that level is reclaimed, the longer-term downtrend remains intact.
On the conference circuit, Siemens Healthineers has been making its case to the diagnostics community. At the Association for Diagnostics & Laboratory Medicine annual meeting in Anaheim, the company received a Top Corporate Supporter award, sharing the spotlight with Roche Diagnostics, Abbott and Danaher. The event, which runs alongside the Clinical Lab Expo with more than 700 exhibitors, has been a platform for the company to showcase its lab diagnostics portfolio and host workshops on liver disease, allergy and immunology.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
Just before the conference, the company announced CE marking for 24 capillary blood test claims on its Atellica CH, IM and CI analyzers — a move designed to give labs more flexibility, particularly for patients where traditional venipuncture is difficult. The product news generated little immediate market reaction, but it underscores the company’s effort to bolster its diagnostics offering even as it considers the unit’s long-term future.
For now, the stock is caught between two forces: a technical recovery that has lifted it off its lows, and a fundamental uncertainty that has yet to be resolved. The third-quarter report will tip the balance one way or the other. If the numbers confirm that costs are under control and the diagnostics slide is slowing, the path toward the 200-day average looks plausible. If not, the recent gains could prove short-lived — and the stock may find itself back where it started.
Ad
Siemens Healthineers Stock: New Analysis - 29 July
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
